Showing results (81-90 of 132) with videos related to

Sort By:
Pageof 14
JTO Clinical and Research Reports|September 30, 2021
Response to Immune Checkpoint Inhibition as Monotherapy or in Combination With Chemotherapy in Metastatic <i>ROS1</i>-Rearranged Lung CancersNoura J Choudhury, Jaime L Schneider, Tejas Patil, et al.
The Journal of Thoracic and Cardiovascular Surgery|August 23, 2023
Superior sulcus non-small cell lung cancers (Pancoast tumors): Current outcomes after multidisciplinary managementKaitlin McLaughlin, Kay See Tan, Joe Dycoco, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 2, 2019
Lesion-Level Response Dynamics to Programmed Cell Death Protein (PD-1) BlockadeJuan C Osorio, Kathryn C Arbour, Dung T Le, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 24, 2025
Molecular characterization of NUT carcinoma: a report from the NUT carcinoma registryJustin J Kim, Sara A Walton, Navin R Mahadevan, et al.
Cancer Immunology Research|March 2, 2016
Autoimmune Bullous Skin Disorders with Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1Jarushka Naidoo, Katja Schindler, Christiane Querfeld, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|April 4, 2026
Safety profile of KRAS G12C inhibitors combined with thoracic radiation therapyDavid Gibbes Miller, Y Helen Zhang, Maria Thor, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 17, 2013
Phase II trial of neoadjuvant bevacizumab plus chemotherapy and adjuvant bevacizumab in patients with resectable nonsquamous non-small-cell lung cancersJamie E Chaft, Valerie Rusch, Michelle S Ginsberg, et al.
Lancet (London, England)|September 17, 2024
Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trialJonathan D Spicer, Marina C Garassino, Heather Wakelee, et al.
Journal for Immunotherapy of Cancer|November 1, 2023
Multi-institutional analysis of aneuploidy and outcomes to chemoradiation and durvalumab in stage III non-small cell lung cancerJoao V Alessi, Adam Price, Allison L Richards, et al.
Cancer Chemotherapy and Pharmacology|July 2, 2013
Risk of hemoptysis in patients with resected squamous cell and other high-risk lung cancers treated with adjuvant bevacizumabMatthew D Hellmann, Jamie E Chaft, Valerie Rusch, et al.
Pageof 14